(Reuters) -Eyenovia said on Friday it would terminate a late-stage study for its experimental drug-device combination to treat an eye disease after failing the main goal of slowing the progression of the condition.
The disease, called pediatric progressive myopia, causes near-sightedness in early childhood, which worsens as the person grows.
An independent committee reviewed the safety and efficacy data from 252 trial participants and found that the rate of myopia progression was not significantly different between the treatment arm and placebo.
The drug developer said it plans to review the data more thoroughly and evaluate strategic alternatives, including a business combination, reverse merger and/or sale of assets.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)
Source link : https://www.medscape.com/s/viewarticle/eyenovia-discontinue-late-stage-study-eye-drug-2024a1000kve?src=rss
Author :
Publish date : 2024-11-15 12:07:35
Copyright for syndicated content belongs to the linked Source.